Document:

EX-10.9

 Exhibit 10.9 

LEASE 
 STREAMWOOD

 ASSOCIATES/HADDONFIELD, LLC 

T/A 
 30 WASHINGTON
AVENUE 
 (“LANDLORD”) 

AND 
 ALTERIX, INC.

 (“TENANT”) 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	PAGE	 
	 1.
	 	 PREMISES
	  	 	1	  
			
	 2.
	 	 TERM
	  	 	1	  
			
	 3.
	 	 RENT
	  	 	1	  
			
	 4.
	 	 PROPORTIONATE AREA
	  	 	2	  
			
	 5.
	 	 LATE PAYMENT
	  	 	2	  
			
	 6.
	 	 USE
	  	 	2	  
			
	 7.
	 	 ALTERATIONS AND TRADE FIXTURES
	  	 	3	  
			
	 8.
	 	 MECHANIC’S LIENS
	  	 	3	  
			
	 9.
	 	 CONDITION OF PREMISES
	  	 	4	  
			
	 10.
	 	 BUILDING SERVICES
	  	 	4	  
			
	 11.
	 	 ASSIGNMENT AND SUBLETTING
	  	 	4	  
			
	 12.
	 	 ACCESS TO PREMISES
	  	 	5	  
			
	 13.
	 	 REPAIRS
	  	 	5	  
			
	 14.
	 	 INDEMNIFICATION AND LIABILITY INSURANCE
	  	 	6	  
			
	 15.
	 	 NEGATIVE COVENANTS OF TENANT
	  	 	7	  
			
	 16.
	 	 FIRE OR OTHER CASUALTY
	  	 	7	  
			
	 17.
	 	 SUBORDINATION AND NON-DISTURBANCE
	  	 	8	  
			
	 18.
	 	 [INTENTIONALLY OMITTED]
	  	 	9	  
			
	 19.
	 	 CONDEMNATION
	  	 	9	  
			
	 20.
	 	 ESTOPPEL CERTIFICATE
	  	 	9	  
			
	 21.
	 	 DEFAULT
	  	 	9	  
			
	 22.
	 	 REMEDIES
	  	 	10	  
			
	 23.
	 	 REQUIREMENT OF STRICT PERFORMANCE
	  	 	11	  
			
	 24.
	 	 LANDLORD’S OBLIGATIONS
	  	 	11	  
			
	 25.
	 	 SUCCESSORS
	  	 	12	  
			
	 26.
	 	 GOVERNING LAW
	  	 	12	  
			
	 27.
	 	 SEVERABILITY
	  	 	12	  
			
	 28.
	 	 CAPTIONS
	  	 	12	  
			
	 29.
	 	 GENDER
	  	 	12	  

  
 i 

							
	 30.
	 	 NOTICES
	  	 	12	  
			
	 31.
	 	 SIGNS
	  	 	13	  
			
	 32.
	 	 ENTIRE AGREEMENT
	  	 	13	  
			
	 33.
	 	 ADDITIONAL SCHEDULES
	  	 	13	  
			
	 34.
	 	 MISCELLANEOUS
	  	 	14	  
			
	 35.
	 	 QUIET ENJOYMENT
	  	 	14	  
			
	 36.
	 	 ENVIRONMENTAL
	  	 	14	  

  
 ii 

 LEASE 

This Lease Agreement, made this      day of September 2015, by and between STREAMWOOD ASSOCIATES/HADDONFIELD, LLC T/A 30
WASHINGTON AVENUE (C/O The Streamwood Company, 30 Washington Avenue Suite A-1, Haddonfield, New Jersey 08033) hereinafter called the “Landlord” and ALTERIX, INC. presently doing business at 625 Clinton Avenue, Haddonfield, NJ 08033
hereinafter called the “Tenant”. 
 WITNESSETH AS FOLLOWS; 

 

	1.	PREMISES 

 Landlord, for and in consideration of the rent to be paid and the
covenants and agreements to be performed by Tenant, as hereinafter set forth, does hereby lease, demise let unto Tenant that space (hereinafter called the “Premises”) situate on the first floor, being Suite F-1 and F-2 as designated on the
first floor plan of Roominders consisting of 1,287 usable square feet plus 222 square feet of common area for a total of 1,509 rentable square feet and situated at 30 Washington Avenue, Haddonfield, New Jersey together with the right to use in
common with the other Tenants in the Building, all common areas including parking as may be limited herein, in Paragraph 6 (b), located rear to building and the non-exclusive use of the walks, access roads and land surrounding the building and the
common areas in the building (sometimes collectively referred to together as “Land and Buildings”. 
  

	2.	TERM 

 (a) The term of this Lease shall be two (2) years, and shall commence
November 1, 2015 and shall terminate at 12:00 Noon on October 31, 2017, unless extended as permitted herein. See Additional Provisions — Exhibit “E”. 

(b) Option To Renew: Tenant shall have two (2) options to renew this Lease for successive terms of two (2) years each under the same
rent terms, conditions and provisions as herein provided (with a 3% yearly increase to base rent as reflected in Section 3. b. hereof). The renewal option, to be effective, must be exercised by Tenant, by written notice of such exercise mailed
to the Landlord no less than (120) days prior to the commencement of any such renewal term. Any such notice of exercise or any such option shall be mailed to Landlord pursuant to the notice provisions hereinafter contained. 

 

	3.	RENT 

 (a) Base Rent: Tenant shall pay to Landlord, without set off or deduction,
except as otherwise permitted herein, by check made payable to 30 WASHINGTON AVENUE at its offices C/O The Streamwood Company, 30 Washington Avenue, Suite A-1, Haddonfield, New Jersey 08033, or such other place as Landlord directs, as yearly
Minimum Annual Rent, also referred to as Base Rent, of $32,020.98 for the first year only, payable in equal monthly installments of $2,668.42 on the first business day of each month in advance during the term of this Lease. TENANT’S SECURITY
DEPOSIT IS $5,336.84. 

  
 1 

											
	 Square Feet
	  	 Year
	  	 Date
	  	Yearly	  	Monthly	  	Per Sq Ft
	 1509
	  	1	  	11/112015	  	$32,020.98	  	$2,668.42	  	$21.22
	 1509
	  	2	  	11/1/2016	  	$32,981.61	  	$2,748.47	  	$21.86
	 1509
	  	Option 1 – Year 1	  	11/1/2017	  	$33,971.06	  	$2,830.92	  	$22.51
	 1509
	  	Option 1 – Year 2	  	11/1/2018	  	$34,990.19	  	$2,915.85	  	$23.19
	 1509
	  	Option 1 - Year 3	  	11/1/2019	  	$36,039,90	  	$3,003.32	  	$23.88
	 1509
	  	Option 1 - Year 4	  	11/1/2020	  	$37,121.09	  	$3,093.42	  	$24.60
	 1509
	  	Option 1 - Year 5	  	11/1/2021	  	$38,234.72	  	$3,186.23	  	$25.34

 (b) Adjustment to Base Rent — Beginning with the second full year of the Lease, and with each successive
year thereafter, the annual Base Rent for each full year within the rental term shall be increased by three (3%) percent per annum. 

(c) In addition the Tenant shall pay the Landlord its proportionate share of all increases in real estate taxes and fire and casualty and
liability insurance from base year 2013 (base year taxes $71,012.50, base year insurance $8,641.00) during the term of this Lease on an annual basis beginning with the commencement date of the Lease. (See Exhibit “H” of this Lease)
Landlord shall provide Tenant with evidence of such increases and receipt confirming payment for Landlord, Tenant shall within thirty (30) days of said notice pay to the Landlord Tenant’s proportionate share of such increases in their
monthly rent. 
 4. PROPORTIONATE AREA: For all purposes of this Lease, the Tenant’s proportionate area attributable to the
Premises shall be 1,509 square feet, which is 6.71% of the total area of the first floor, second floor and lower level of entire building. 
  

	5.	LATE PAYMENT 

 Rent is due and payable on or before the first day of each month.
Rent received after the tenth (10th) of the month is subject to a late charge of five (5%) which charge must accompany rent. 
  

	6.	USE 

 (a) Tenant shall use and occupy the Premises for office space and related
purposes. No machinery, equipment or other thing that could cause unusual vibration or noise shall be installed or placed therein. Tenant shall not use or occupy the Premises for any other purpose or business without the prior written consent of
Landlord. Tenant shall observe and comply with the Rules and Regulations attached hereto as Exhibit “B” and may be amended from time to time provided such amendments do not materially adversely affect Tenant’s use of the Premises, as
well as all applicable laws and governmental regulations and to all reasonable requirements of the insurer of the Premises or the Building or property which the Premises are a part. All such Rules and Regulations shall apply to Tenant and its
employees, agents, licensees, invitees, subtenants and contractors. Tenant shall not subject any portion of the floor to greater loading than that portion of the Premises is designed to carry and which Landlord has advised Tenant. 

  
 2 

 (b) Tenant will have the use of parking spaces in common parking lot in rear of the Building plus
the non-exclusive, periodic use of delivery spaces for deliveries only. 
  

	7.	ALTERATIONS AND TRADE FIXTURES 

 Tenant will, during the term and all
continuations hereof, keep, and at the expiration hereof, peaceably surrender possession of the Premises in as good order and condition as existed at the inception of this Lease, reasonable wear and tear and damage by fire, elements or casualty
excepted, and will, at the expiration of said term, or any continuation thereof, deliver the keys at the office of said Landlord. Tenant shall have the right to make any reasonable alterations, additions, or improvements with Landlord’s prior
written consent which consent shall not be unreasonably withheld and all alterations, additions or improvements made by either of the parties hereto upon the Premises, except moveable and detached or detachable office furniture, and moveable
partitions, and moveable machinery and equipment installed at Tenant’s expense, shall be the property of Landlord, and shall remain upon and be surrendered with the termination of this Lease. Any damages caused by or arising from the
Tenant’s removal of its property from the Premises shall be restored and repaired at Tenant’s expense. 
 Any property or fixtures
which remain upon the Premises after the expiration of the Lease shall be deemed abandoned by Tenant and Landlord may take possession of same and dispose of in any reasonable manner without any further liability of Landlord to Tenant. Any cost
associated with the removal of such property shall be payable by Tenant. 
 All labor and materials furnished by or on behalf of Tenant
under or pursuant to this Lease shall be first class, not less than the caliber and quality which exists in the quality which exists in the Premises and by contractors approved in writing by Landlord, which approval shall not be unreasonably
withheld, and shall be accomplished at times so as not to materially disturb the activities of other tenants. Tenant shall not install any alterations, additions, or improvements in such manner as to comprise the structural integrity of the Premises
or any part thereof. The labor and materials shall be installed in complete conformity to all applicable statues, codes, ordinances and regulations. 
  

	8.	MECHANIC’S LIENS 

 If an mechanics’ or other lien shall be filed against
the Premises or the Building for labor or material furnished or to be furnished at the request of the Tenant, then Tenant shall at its expense cause such lien to be discharges of record by payment, bond or otherwise, within thirty (30) days
after the filing thereof. If Tenant shall fail to cause such lien to be discharged of record within such thirty (30) day period, Landlord may cause investigation as to the validity thereof or as to any offsets or defenses thereto. Any
reasonable cost to Landlord for removal of such lien will be charged to Tenant as additional rent and payable on the first day of the month next following the payment by Landlord. Tenant shall indemnify and hold Landlord harmless against any and all
claims, costs, damages, liabilities and expenses (including reasonable attorney fees) which may be brought or imposed against or incurred by Landlord by reason of any such lien or its discharge. 

  
 3 

	9.	CONDITION OF PREMISES 

 Tenant acknowledges and agrees that, except as expressly
set forth in this Lease, there has been no representations or warranties made by or on behalf of Landlord with respect to the Premises. Landlord represents and warrants that Tenant’s proposed use of the Premises for office space is permitted
under all applicable laws and zoning ordinances. if Landlord is required to complete any work in order to place them in a condition for occupancy by Tenant then the specifications for any such new construction shall be as set forth on the attached
Exhibit “E”. The taking of possession of the Premises by Tenant shall conclusively establish that the Premises were at such time in satisfactory condition, order and repair. 

 

	10.	BUILDING SERVICES 

 (a) Landlord shall provide and pay for the following services
and facilities. 
  

	 	(1)	Air Conditioning, ventilating and heating for leased and common areas. 

  

	 	(2)	Electric current in such reasonable quality as may be required by Tenant For the operation of the lighting fixtures, typical office computer needs and electrical outlets existing upon the Premises as of the date Tenant
takes possession of the Premises. 

  

	 	(3)	Janitorial and utilities of the common areas including cleaning and maintenance of common areas, restrooms, lobbies, hallways and elevators. 

 

	 	(4)	Janitorial three times a week for Tenant’s leased space. 

  

	 	(5)	Exterior lighting; landscaping; snow, ice and debris removal. 

  

	 	(6)	Water and sewer service. 

  

	11.	ASSIGNMENT AND SUBLETTING 

 (a) Subject to Exhibit E, Tenant shall have no right
to assign or sublet all or any part of the Premises without the prior written approval of Landlord which approval shall not be unreasonably withheld. On any approved assignment or subletting of all or any part of the Premises, (I) Landlord
shall receive from Tenant all profit derived by Tenant from the assignment or subletting, and (2) The sub-tenant or assignee shall be required to enter into a written Agreement with Landlord whereby it agrees to be bound by all terms and
conditions of the Lease and to pay all rents due directly to Landlord. 
 (b) The written approval of Landlord to one or more sublettings or
assignments shall not operate as a waiver of Landlord’s right to approve any further sublettings and assignments as provided herein. 

  
 4 

 (c) Notwithstanding the foregoing, Landlord’s consent shall not be required in connection
with an assignment or subletting to a parent, subsidiary, or affiliate of the Tenant, or corporation of which Tenant is a majority shareholder, or in connection with a merger, consolidation or similar corporate transaction in which Tenant engages so
long as either the Tenant or the surviving entity remain primarily liable and the assignee or sublessee enters into an agreement with Landlord agreeing to be bound by all of the terms and conditions of this Lease. 

 

	12.	ACCESS TO PREMISES 

 Landlord, its employees and agents upon prior reasonable
notice to Tenant (except in cases of emergency) shall have the right to enter the Premises, with a representative of Tenant present, at all reasonable times for the purpose of examining or inspecting the same, showing the same to prospective
purchasers, mortgagees or tenants of the Building, and making such alterations, repairs, improvements or additions to the Premises or to the Building as may be necessary, provided that Landlord uses its best efforts to complete such alteration,
repair, improvement or addition with minimum disturbance to Tenant’s operations. If representatives of Tenant shall not be present to open and permit entry into the Premises at any time when such entry is necessary, Landlord may enter by a
master key (or forcibly in the event of an emergency) without liability to Tenant except for damages to the Premises or inventory, fixtures or equipment caused by the negligence of Landlord or Landlord’s agent and without such entry
constituting an eviction of Tenant or termination of this Lease. 
  

	13.	REPAIRS 

 (a) Tenant, at its sole cost and expense and throughout the term of this
Lease, shall maintain the interior of the Premises in clean condition (including carpeting) free of accumulation of dirt and rubbish. Other than this obligation and Tenant’s obligation to repair any damage caused by the misuse or negligence of
Tenant, its agents or employees, Landlord shall keep and maintain the Premises and all common areas in good order and condition. When used in this Article 13, the term “repairs” shall include replacements and renewals when necessary. All
repairs made by Landlord or Tenant shall utilize materials and equipment which are at least equal in quality to those originally used in constructing the Building and the Premises. 

(b) Landlord, throughout the term of this Lease and at Landlord’s sole cost and expense, shall make all necessary repairs to the footings
and foundations and the structural steel columns and girders forming a part of the Premises, together with the roof, HVAC system, other mechanical and electrical systems and other capital items. Tenants shall pay the cost of any repairs made
pursuant to this paragraph if same are occasioned by the negligent act or omission of Tenant, its employees or invitees. 
 (c) Landlord
shall not be liable by reason of any injury to or interference with Tenant’s business arising from the making of any repairs, alterations, additions or improvements in or to the Premises or the Building or to any appurtenances or equipment
therein except as may have occurred by reason of the willful misconduct or improper or negligent acts of Landlord and/or omissions of Landlord. There shall be no abatement of rent because of such repairs, alterations, additions or improvements,
except as set forth in this paragraph or “Fire and other Casualty” Section hereof. 

  
 5 

 (d) Except as provided in Paragraph 16 or 18, upon termination of this lease Tenant shall return
the Premises to Landlord broom clean and in as good order as existed at the inception of this Lease, reasonable wear and tear and damage by fire, elements or casualty excepted. 

(e) In the event the Landlord, following written notice from the Tenant, fails to make repairs required of it within three (3) days, the
Tenant may proceed to make such repairs and charge the Landlord accordingly or offset such charge against rent. 
  

	14.	INDEMNIFICATION AND LIABILITY INSURANCE 

 (a) Tenant, shall indemnify, hold
harmless and defend Landlord from and against any and all costs, expenses (including reasonable counsel fees), liabilities, losses, damages, suits, actions, fines, penalties, claims or demands of any kind and asserted by or on behalf of any person
or governmental authority, arising out of or in any way caused by the Tenant’s possession of the Premises, and Landlord shall not be liable to Tenant on account of (i) any failure by Tenant to perform any of the agreements, terms,
covenants or conditions of this Lease required to be performed by Tenant, (ii) any failure by Tenant to comply with any statues, ordinances, regulations or orders of any governmental authority where compliance by Tenant is required, or
(iii) any accident, death or personal injury, or damage to property, which shall occur in or about the Premises except as the same may be caused by the willful misconduct or wrongful or negligent act or omission of Landlord, its employees,
invitees or agents. 
 (b) Landlord shall indemnify, hold harmless, and defend Tenant from and against any and all costs, expenses
(including reasonable counsel fees), liabilities, losses, damages, suits, actions, fines, penalties, claims, or demands of any kind and asserted by or on behalf of any person or governmental authority, arising out of or in any way connected with
Landlord’s ownership of the Land and Building, and Tenant shall not be liable to Landlord on account of (i) any failure by Landlord to perform any of the agreements, terms, covenants, or conditions of this Lease required to be performed by
Landlord, (ii) any failure by Landlord to comply with any statues, ordinances, regulations, or orders of any governmental authority, or (iii) any accident, death or personal injury, or damage to property, which shall occur in or about the
Land and Building except as the same may be caused by the willful misconduct or wrongful or negligent act of Tenant, its employees or agents. 

(c) During the term of this Lease or arty renewal thereof, Tenant shall obtain and promptly pay all premiums for comprehensive general
liability insurance against claims for personal injury, death or property damage occurring upon, in or about Premises demised to Tenant, with minimum limits of $1,000,000.00 combined bodily injury and property damage with such insurance company or
companies as shall be reasonably satisfactory to Landlord from time to time, and all such policies and renewals thereof shall name the Landlord as an additional insured. On or before the Commencement Date of the term of this Lease, and thereafter
not less than fifteen (15) days prior to the expiration dates of said policy of policies, Tenant shall provide copies of policies or certificates of insurance evidencing coverage required by this Lease. 

(d) During the term of this Lease or any renewal thereof, Landlord shall obtain and promptly pay all premiums for comprehensive general
liability insurance against claims for 

  
 6 

 
personal injury, death or property damage occurring upon, in or about Premises and common areas, with minimum limits of $1,000,000.00 combined bodily injury and property damage. On or before the
Commencement Date of the term of this Lease, and thereafter not less than fifteen (15) days prior to the expiration dates of said policy of policies, Landlord shall provide copies of policies or certificates of insurance evidencing coverage
required by this Lease. 
 (e) All policies of insurance identified in this Lease shall (to the extent possible) provide: (i) that no
material change or cancellation of said policies shall be made without thirty (30) days prior written notice to Landlord, (ii) that any loss shall be payable notwithstanding any act or negligence of the Landlord which might otherwise
result in the forfeiture of said insurance, and (iii) that the insurance company issuing the same shall have no right of subrogation against the Landlord or Tenant, as the case may be. 

 

	15.	NEGATIVE COVENANTS OF TENANT 

 Tenant agrees that it will not do or suffer to be
done, any act, matter or thing whereby the fire insurance or any other insurance now in force or hereafter to be placed on the Premises or any part thereof, or on the Building of which the Premises is a part, shall become void or suspended, or
whereby the same shall be rated as a more hazardous risk than at the date when Tenant received possession hereunder. In case of a breach of this covenant, Tenant agrees to pay to Landlord as additional rent, any and all increase or increases of
premiums on insurance carried by Landlord on the Premises, or any part thereof, or on the building of which the Premises is a part, directly caused by the said act, matter or thing. 

 

	16.	FIRE OR OTHER CASUALTY 

 (a) If the Premises are damaged by fire or other
casualty, the damages shall be repaired by and at the expense of Landlord and the rent and other charges until such repairs shall be made shall be apportioned from the date of such fire or other casualty according to the part of the Premises that is
usable by Tenant. Landlord agrees to repair such damage within a reasonable period of time after the occurrence of fire or other damage, except that Tenant shall be responsible to repair and replace its own furniture, furnishings, equipment and any
alteration or improvement installed by Tenant, Landlord shall not be liable for any inconvenience or annoyance to Tenant or injury to the business of Tenant resulting from such damage or the repair thereof. All repairs shall be performed with due
diligence and in a good and workmanlike manner. 
 (b) If the Premises are rendered substantially untenantable by fire or other casualty,
and the Premises cannot be fully restored within 120 days of the date of casualty, Tenant shall have the option to terminate the Lease upon written notice to Landlord. 

(c) If the Premises, in the opinion of Landlord’s licensed architect or engineer, are rendered substantially untenantable by reason of
such fire or other casualty, and less than six (6) months remain on the Lease term from the date of loss, including any options to renew, then Landlord shall have the right to be exercised by notice in writing delivered to the Tenant within
thirty (30) days from and after said occurrence, to elect to terminate this Lease, and, in such event, this Lease and the tenancy hereby created shall cease as of the date of said occurrence, the rent to be adjusted as of said date. 

  
 7 

 (d) Landlord shall procure and maintain the following insurance coverage during the term and all
renewal periods at Landlord’s expense, subject to reimbursement as set forth in this Lease: “all-risk” (also known as “causes of loss — special form”) property damage insurance on all buildings and common area
improvements, to the extent insurable, for the full replacement cost of such buildings and improvements. Such insurance shall be issued for periods of not less than one (1) year by companies having an AM Best rating of A- or better (or
equivalent) and authorized to issue such insurance in the state in which the Premises is located. The policy or policies shall provide that any loss will be paid notwithstanding any act or negligence of Landlord, Tenant or any other tenant or
occupant. Upon request by Tenant, Landlord shall deliver to Tenant copies of certificates evidencing the policies (ACORD or equivalent standard form). The certificates of insurance shall provide that no lapse, cancellation or material modification
of the policy shall be effective until at least twenty (20) days after mailing of written notice thereof to Tenant. All loss proceeds payable under any insurance required of Landlord under this Section (d) shall be disbursed and utilized
solely for the purpose of repairing and restoring the buildings and improvements. 
 (e) In the event that the insurance proceeds obtained
as a result of fire or other casualties set forth within this paragraph 16, are not sufficient to fully repair and restore the Premises, then the Tenant has the right to contribute the deficiency for purposes of such repair or restoration. In the
event that the Premises are totally destroyed by fire or other casualty, and the Tenant does not put up any money related to rebuilding, and the Landlord rebuilds the Premises, the Tenant shall have the right of first refusal with respect to that
portion of the new building which otherwise would have been occupied by Tenant on the same terms and conditions as provided, herein. 
  

	17.	SUBORDINATION AND NON-DISTURBANCE 

 This Lease is subject and subordinate to all
mortgages now or hereafter affecting or covering the Premises and all or any part of the Building and to all renewals, modifications, replacements or extensions thereof. Notwithstanding the aforesaid subordination, in the event of the foreclosure of
any such mortgage, (a) this Lease shall not terminate, and (b) the peaceful possession of Tenant shall not be disturbed, provided that Tenant is not in default under any of the terms and conditions of this Lease. Tenant agrees to attorn to
and to recognize the mortgagee or the purchaser at foreclosure sale as Tenant’s landlord for the balance of the term of this Lease. Tenant hereby agrees, however, that such mortgagee or the purchaser at foreclosure sale shall not be
(i) liable for any act or omission of Landlord, (ii) subject to any offsets or defenses which Tenant might have against Landlord, (iii) bound by any rent or additional rent which Tenant may have paid to Landlord for modification of
this Lease made without its consent. The aforesaid subordination, non-disturbance and attornment provisions shall be self-operative; however Tenant agrees to promptly execute any other agreement submitted by Landlord in confirmation or
acknowledgment of same. 

  
 8 

	18.	[INTENTIONALLY OMITTED] 

  

	19.	CONDEMNATION  

 (a) if the whole of the Premises shall be condemned or taken
either permanently or temporarily for any public or quasi-public use of purpose, under any statute or by right of eminent domain, or by private purchase in lieu thereof, then in that event the term of this Lease shall cease and terminate from the
date when possession is taken thereunder pursuant to such termination and any rent paid for a period thereafter shall be refunded. In the event of a partial condemnation, the rental paid by the Tenant to the Landlord shall be reduced, such reduction
to be proportionate to the partial taking, such partial condemnation not to otherwise affect this Lease unless the partial taking materially adversely affects the operation of Tenant in Tenant’s sole, but reasonable discretion in which event
the Tenant shall have the right to terminate this lease upon forty five (45) days prior written notice to landlord. In the event more than 15% of the Premises or more than 15% of the Building containing same shall be so taken (or if more than
fifteen percent (15%) of the parking areas are taken and not promptly replaced with contiguous parking areas) then Tenant or Landlord may elect to terminate this Lease from the date when possession is taken thereunder pursuant to such
proceedings or purchase or, upon mutual agreement of the parties, Landlord shall repair and restore, at its own expense, the portion not taken and thereafter the rent shall be reduced proportionately to the portion of the Premises taken. 

(b) In the event of any total or partial taking of the Premises or the Building, Landlord shall be entitled to receive the entire award in
such proceeding for the Building and land and Tenant shall make a separate application for Tenant’s fixtures, equipment and moving expenses under the then applicable New Jersey eminent domain code. 

 

	20.	ESTOPPEL CERTIFICATE 

 Tenant shall, at any time and from time to time, within
fifteen (15) days after written request by Landlord, execute, acknowledge and deliver to Landlord, or its mortgagee or trustee, a statement in writing duly executed by Tenant (i) certifying that this Lease is in full force and effect (if
that be the case) without modification or amendment (or, if there have been any modifications or amendments, that this Lease is in full force and effect as modified and amended and setting forth the modifications and amendments),
(ii) certifying the dates to which Base Rent and additional rent have been paid, and (iii) either certifying that to the knowledge of the Tenant no default exists under this Lease or specifying each such default; it being the intention and
agreement of Landlord and Tenant that any such statement by Tenant may be relied upon by a prospective purchaser or a prospective or current mortgagee of the Building, or by others, in any matter affecting the Premises. 

 

	21.	DEFAULT 

 The occurrence of any of the following shall constitute a default and
breach of this Lease by Tenant. 
 (a) failure of Tenant to accept possession of the Premises within ninety (90) days after the date of
commencement providing the Premises is ready for occupancy; 

  
 9 

 (b) failure by Tenant to pay, when due, any installment of rent hereunder or any additional rent
or any such other sum herein required to be paid by Tenant, following the expiration of thirty (30) days written notice from Landlord to Tenant; 

(c) a failure by Tenant to observe and perform any other provisions or covenants of this Lease to be observed or performed by Tenant, where
such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant provided, however, that if the nature of the default is such that the same cannot reasonably be cured within such thirty (30) day period,
Tenant shall not be deemed to be in default if Tenant shall within such period commence such cure and thereafter diligently prosecute the same to completion; 

(d) the filing of a petition by or against Tenant for adjudication as a bankrupt or insolvent or for its reorganization or for the appointment
pursuant to any local, state or federal bankruptcy or insolvency law of a receiver or trustee of Tenant’s property; or an assignment by Tenant for the benefit of creditors; or the taking of possession of the property of Tenant by any local,
state or federal governmental officer or agency of court appointed official for the dissolution or liquidation of Tenant or for the operating, either temporary or permanent, of Tenant’s business; provided, however, that if any such action is
commenced against Tenant the same shall not constitute a default if Tenant causes the same to be dismissed within sixty (60) days after the filing of same. 
  

	22.	REMEDIES 

 Upon the occurrence of any such event of default set forth above: 

(a) Landlord may (but shall not be required to) perform for the account of Tenant any such default of Tenant and immediately recover as
additional rent any expenditure made and the amount of any obligations incurred in connection therewith plus interest at the rate of 2% per annum over the PNC prime rate (as it may be adjusted from time to time) from the date of such
expenditure; 
 (b) Landlord, at its option, may serve notice upon Tenant that this Lease and the then unexpired term hereof and all renewal
options shall cease and expire and become absolutely void on the date specified in such notice, to be not less than five (5) days after the date of such notice without any right on the part of the Tenant to save the forfeiture by payment of any
sum due or by the performance of any terms provisions, covenant, agreement or condition broken; and, thereupon and at the expiration of the time limit in such notice, (not to exceed thirty (30) days) this Lease and the term hereof granted, as
well as the right, title and interest of the Tenant hereunder, shall wholly cease and expire and become void in the same manner and with the same force and effect (except as to Tenant’s liability) as if the date fixed in such notice were the
date herein granted for expiration of the term of this Lease. Thereupon, Tenant shall immediately quit and surrender to Landlord the Premises, and Landlord may enter into and repossess the Premises by summary proceedings, detained, ejectment or
otherwise and remove all occupants thereof and, at landlord’s option, any property thereon without being liable to indictment, prosecution or damages therefore. No such expiration or termination of this Lease shall relieve Tenant of its
liability and obligations under this Lease, whether or not the Premises shall be relet. Landlord may accelerate ail base rent for the balance of the term of this Lease and declare the same to be immediately due and payable, subject to the ability of
the Landlord to make a good faith effort to mitigate damages. 

  
 10 

 (c) Landlord may, at any time after the occurrence of any event of default, following notice of
termination and the expiration of any period provided therein re-enter and repossess the Premises and any part thereof and attempt in its own name, as agent for Tenant or on its own behalf, to relet all or any part of such Premises for and upon such
terms to anyone; for the purpose of such reletting, Landlord may decorate or make reasonably necessary repairs, changes, alterations or additions which shall be charged to and be payable by Tenant as additional rent hereunder, as well as any
reasonable brokerage and legal fees expended by Landlord, and any sums collected by Landlord from any new Tenant obtained on account of the Tenant shall be credited against the balance of the rent due hereunder as aforesaid. Tenant shall pay to
Landlord monthly, on the days when the rent would have been payable under this Lease, the amount due hereunder less the amount obtained by Landlord from such new Tenant. 

(d) Landlord shall have the right of injunction, in the event of a breach or threatened breach by Tenant of any of the agreements, conditions,
covenants or terms hereof, to restrain the same and the right to invoke any remedy allowed by law or in equity, whether or not other remedies, indemnity or reimbursements are herein provided. The right and remedies given to Landlord in this Lease
are distinct, separate and cumulative remedies; and no one of them, whether or not exercised by Landlord, shall be deemed to be in exclusion of any of the others. 

(e) In addition to all remedies provided herein or by law, the non-prevailing party shall pay to the prevailing party, reasonable
attorneys’ fees and court costs incurred as a result of litigation related to such breach. 
  

	23.	REQUIREMENT OF STRICT PERFORMANCE 

 The failure or delay on the part of either
party to enforce or exercise at any time any of the provisions, rights or remedies in the Lease shall in no way be construed to be a waiver thereof, nor in any way to affect the validity of this Lease or any part hereof, or the right of the party to
thereafter enforce each and every such provision, right or remedy. No waiver of any breach of this Lease shall be held to be a waiver of any other of subsequent breach. The receipt by Landlord of rent at a time when the rent is in default under this
Lease shall not be construed as a waiver of such default. The receipt by Landlord of a lesser amount than the rent due shall not be construed to be other than a payment on account of the rent then due, nor shall any statement on Tenant’s check
or any letter accompanying Tenant’s check be deemed an accord and satisfaction, and Landlord may accept such payment without prejudice to Landlord’s right to recover the balance of the rent due or to pursue any other remedies provided in
this Lease. No act or thing done by Landlord or Landlord’s agents or employees during the term of this Lease shall be deemed an acceptance of a surrender of the Premises, and no agreement to accept such surrender shall be valid unless in
writing and signed by Landlord. 
  

	24.	LANDLORD’S OBLIGATIONS 

 Landlord agrees to maintain the Premises as a first
class building. Landlord’s obligations hereunder shall be binding upon Landlord only for the period of time that Landlord is in 

  
 11 

 
ownership of the Building; and, upon termination of that ownership, Tenant, except as to any obligations which have then matured, shall look solely to Landlord’s successor in interest in the
building for the satisfaction of each and every obligation of Landlord hereunder. 
  

	25.	SUCCESSORS 

 The respective rights and obligations provided in this Lease shall
bind and inure to the benefit of the parties hereto, their legal representatives, heirs, successors and assigns; provided, however, that no rights shall inure to the benefit of any successors of Tenant unless Landlord’s written consent for the
transfer to such successor has first been obtained as provided in paragraph 11 hereof. 
  

	26.	GOVERNING LAW 

 This Lease shall be construed, governed and enforced in accordance
with the laws of the State of New Jersey. 
  

	27.	SEVERABILITY 

 If any provisions of this Lease shall be held to be invalid, void
or unenforceable, the remaining provisions hereof shall in no way be affected or impaired and such remaining provisions shall remain in full force and effect. 
  

	28.	CAPTIONS 

 Marginal captions, titles or Exhibits and Riders and the table of
contents in this Lease are for convenience and reference only, and are in no way to be construed as defining, limiting or modifying the scope or intent of the various provisions of this Lease. 

 

	29.	GENDER 

 As used in this Lease, the word “person” shall mean and
include, where appropriate, an individual, corporation, partnership or other entity; the plural shall be substituted for the singular, and the singular for the plural, where appropriate; and the words of any gender shall mean to include any other
gender. 
  

	30.	NOTICES 

 Wherever in this Lease it shall be required or permitted that notice or
demand be given or served by either party to this Lease to or on the other party, such notice or demand shall be deemed to have been duly given or served if in writing and either personally served or forwarded by Registered or Certified Mail,
postage prepaid, or by overnight delivery; and addressed as follows: 
  

			
	 To Landlord:
	  	Streamwood Associates/Haddonfield, LLC
		  	C/O The Streamwood Company
		  	30 Washington Avenue
		  	Suite A-1
		  	Haddonfield, NJ 08033

  
 12 

			
	 To Tenant:
	  	Alterix, Inc.
		  	Attention: Patrick Mooney
		  	30 Washington Avenue, Suite F-1
		  	Haddonfield, New Jersey 08033

 Each such mailed notice shall be deemed to have been given to or served upon the party to which addressed two days after the
date the same is deposited in the United States Registered or Certified Mail, postage prepaid, and properly addressed in the manner above provided. Personal or overnight delivery shall be deemed complete when delivered. Either party hereto may
change its address to which said notices shall be delivered or mailed by giving written notice of such change to the other party hereto as herein provided. 
  

	31.	SIGNS 

 Tenant will be permitted one exterior door plus established directory
signs. Tenant shall have the right to place a sign reasonably acceptable to Landlord in space provided by Landlord. Tenant shall not post any sign or other listing in the windows or upon the exterior of the Building. Landlord will have sign painted
and installed at Tenant’s expense. 
  

	32.	ENTIRE AGREEMENT 

 This Lease, including the Exhibits and any Riders hereto,
contains all the agreements, conditions, understandings, representations and warranties made between the parties hereto with respect to the subject matter hereof, and may not be modified orally or in any manner other than by an agreement in writing
signed by both parties hereto or their respective successors in interest. 
  

	33.	ADDITIONAL SCHEDULES 

 The following additional schedules are attached hereto and
made a part of this Lease: 
  

			
	 Exhibit A:
	  	Tenant Estoppel
	 Exhibit B:
	  	Rules and Regulations
	 Exhibit C:
	  	Sign Criteria
	 Exhibit D:
	  	Parking Spaces
	 Exhibit E:
	  	Additional Provisions
	 Exhibit F:
	  	Sketch of Premises and Entire Building
	 Exhibit G:
	  	Percentages of Leased Space
	 Exhibit H:
	  	Tax & Insurance Increases — Example

  
 13 

	34.	MISCELLANEOUS 

 (a) Landlord will not unreasonably withhold or delay
Landlord’s consent whenever such consent is required to be given. 
 (b) Landlord shall comply with all laws, rules, ordinances and
regulations pertaining to Landlord’s ownership and operation of Premises and the Building. 
  

	35.	QUIET ENJOYMENT 

 The Landlord represents and warrants that it is the owner of the
Premises, and that the Tenant, upon payment of rents and performance of the conditions, covenants, promises and agreements to be performed by it herein contained, shall and may peaceably possess and enjoy the Premises and common areas during the
term of this lease without any interruption or disturbance. 
  

	36.	ENVIRONMENTAL 

 The Landlord represents and warrants that, to its knowledge, there
are no adverse environmental conditions affecting the Premises or the building or the property on which the building is located. 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Lease and have initialed the
Exhibits and any Riders hereto, the day and year first above written. 
  

			
	LANDLORD:
	Streamwood Associates/Haddonfield, LLC
		
	By:	 	 /s/ John F. Leonard

		 	John F. Leonard
		 	Managing Partner
	
	TENANT:
	ALTERIX, INC. NC.
		
	By:	 	 /s/ Patrick Mooney

		 	Patrick Mooney
		 	Corporate Representative

  
 15EX-10.10

 Exhibit 10.10 

INTELLECTUAL PROPERTY PURCHASE AGREEMENT 

THIS INTELLECTUAL PROPERTY PURCHASE AGREEMENT (the “Agreement”) is entered into as of October 24, 2015 (the “Effective
Date”) by and between BioChemics, Inc., a Delaware corporation having an address at 300 Rosewood Drive, Suite 103, Danvers MA 01923 (“BioChemics”) and Inpellis, Inc., a Delaware corporation having an address at 30
Washington Avenue, Suite F, Haddonfield, NJ 08033 (“Inpellis”). 
 RECITALS 

WHEREAS, BioChemics owns certain assets, rights, intellectual property and know-how related to designing, developing and using transdermal, intra-dermal and
topical drug delivery technology (the “BioChemics Intellectual Property”); and 
 WHEREAS, BioChemics desires to sell to Inpellis, and Inpellis
desires to purchase from BioChemics, full ownership of certain of the BioChemics Intellectual Property and joint ownership of certain of the BioChemics Intellectual Property; and 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
  

	1.	Definitions and Interpretation 

 The following words have the following meaning when used
in this Agreement. 
 1.1 “Affiliate” means any corporation, company, partnership, joint venture or other entity which Controls, is
Controlled by, or is under common Control with a Party (as hereinafter defined), as the case may be. For the purpose of this definition, “Control” of an entity means the ownership, directly or indirectly, of more than fifty percent
(50%) of the outstanding voting securities or capital stock of such entity, or the legal power to direct or cause the direction of the general management and policies of the entity in question. For purposes of this definition, BioChemics shall
not be considered an Affiliate of Inpellis. 
 1.2 “BioChemics Intellectual Property” means (a) Know-How (as hereinafter
defined) that relates to the BioChemics VALE (Vaso Active Lipid Encapsulated) technology and the Products Controlled by BioChemics as of the Effective Date or that is or was either conceived by BioChemics independently at any time, whether or not
patents are applied for or issued to BioChemics and (b) Patents or Joint Patents owned by BioChemics that claim or are directed to be the foregoing Know-How. 

1.3 “Commercialize” or Commercialization” shall mean any and all activities, excluding Development or manufacturing, necessary or
desirable to realize and maximize commercial sales of each of the Products in accordance with applicable law, including distributing, importing, transporting, customs clearance, export, warehousing, packing, handling and delivering to

 
customers, as well as offering for sale and sales, marketing, promoting and reimbursement related activities, including booking sales. When used as a verb “Commercialize” means to
engage in Commercialization 
 1.4 “Confidential Information” of a Party means trade secrets or confidential or proprietary
information, whether written, oral or in any other form, designated as such in writing (e-mail is sufficient) by such Party, including by letter or by the use of an appropriate proprietary stamp or legend, prior to or at the time any such trade
secret or confidential or proprietary information is disclosed by such Party to the other Party. Confidential Information disclosed in oral form shall be deemed Confidential Information only to the extent that it is confirmed in writing to the other
Party within twenty (20) days after the date of oral disclosure. 
 1.5 “Develop” or “Development” shall mean
all activities relating to research and development in connection with seeking obtaining and/or maintaining any Regulatory Approval (as hereinafter defined) of the Products including without limitation all pre-clinical research and development
activities, all human clinical studies and all other activities relating to seeking, obtaining and/or maintaining any Regulatory Approval from FDA or other Regulatory Authority (as hereinafter defined). 

1.6 “FDA” means the United States Food and Drug Administration, or any successor agency thereto having the administrative authority to
regulate the marketing of human pharmaceutical products or biological therapeutic products, delivery systems and devices in the United States of America. 

1.7 “Field” shall mean the prescriptive prophylactic or therapeutic treatment of pain in humans other than in the skin
(‘non-dermal pain”) with the products and actives specified in Schedule 1.15. 
 1.8 Reserved. 

1.9 “Joint Patents” means patents and patent application owned by BioChemics that are not Patents as defined in Section 1.14
below and any substitutions, extensions, additions, reissues, reexaminations, renewals, divisions, continuations, continuations-in-part or supplementary protection certificates thereof, and all foreign counterparts of any of the foregoing, existing
as of the consummation of the Agreement (the “Closing”, and the date upon which the Closing occurs, the “Closing Date”). The Joint Patents are set forth on Schedule 1.9. 

1.10 “Know-How” means all know-how, show-how, proprietary technical and non-technical information, trade secrets, formulae,
techniques, sketches, drawings, materials, models, inventions, designs, specifications, processes, apparatus, equipment, databases, research, experimental work, development, pharmacology and clinical data, software programs and applications,
software source documents, and any related type of proprietary intellectual property right or other information other than the Patents and Joint Patents. 

  
 2 

 1.11 “NDA” means a New Drug Application as defined in the U.S. Food, Drug and Cosmetics
Act and the regulations promulgated thereunder and any corresponding or equivalent foreign application or registration. 
 1.12
“Party” means BioChemics or Inpellis. If either Party assigns this Agreement to any of its Affiliates in accordance with and subject to Section 7.8, “Party” shall include such Affiliate of such Party. 

1.13 “Patent Authority” means a governmental, intergovernmental, or government-authorized body responsible for receiving, examining,
issuing, extending or maintaining patents. 
 1.14 “Patents” mean patents and patent application owned by BioChemics relating to or
that cover, in whole or part, the composition, use, manufacture, distribution, marketing, promotion, sale, administration or formulation of the Products and any substitutions, extensions, additions, reissues, reexaminations, renewals, divisions,
continuations, continuations-in-part or supplementary protection certificates thereof, and all foreign counterparts of any of the foregoing, existing as of the consummation of the Agreement (the “Closing”, and the date upon which the
Closing occurs, the “Closing Date”). The Patents are set forth on Schedule 1.14. 
 1.15 “Products” shall mean the
pharmaceutical products set forth on Schedule 1.15. 
 1.16 “Regulatory Approval” means any approvals (including price and reimbursement
approvals), licenses, registrations, or authorizations of a Regulatory Authority. 
 1.17 “Regulatory Authority” means any national,
supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, whose approval or authorization is necessary for, or to whom notice must be given prior to, the manufacture,
distribution, use, import, transport and/or sale of a Product in such jurisdiction. 
 1.18 “Third Party” means any Party other than the
Parties and their Affiliates. 
 In this Agreement headings are for convenience only and do not affect interpretation, and unless the
context indicates a contrary intention: 
 (a) if a word or phrase is given a defined meaning, any other part of speech or grammatical form
of that word or phrase has a corresponding meaning; 
 (b) a Section, schedule, attachment or Exhibit to this Agreement forms a part of this
Agreement, but if there is inconsistency between this Agreement and any schedule, attachment or Exhibit to it, this Agreement shall prevail unless the Parties have agreed otherwise in writing; 

(c) a reference to a document (including this Agreement) is to that document as varied, novated, ratified or replaced from time to time; 

(d) a reference to a statute includes its delegated legislation, and a reference to a statute or delegated legislation or a provision of
either includes consolidations, amendments, reenactments and replacements; 

  
 3 

 (e) a reference to “includes” in any form is not a word of limitation; 

(f) the captions and headings of clauses contained in this Agreement preceding the text of the Sections, sections, subsections and paragraphs
hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction; 

(g) references to days shall mean calendar days, unless otherwise specified; 

(h) ambiguities and uncertainties, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to
have caused the ambiguity or uncertainty to exist; and 
 (i) this Agreement has been prepared in the English language and the English
language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language.

  

	2.	Sale to Inpellis 

 2.1 BioChemics Sale of Patents to Inpellis. BioChemics hereby sells,
transfers, conveys, assign and delivers to Inpellis for the consideration specified below, all right, title and interest in (a) the Patents, (b) all Know-How and other intellectual property of BioChemics directly related to the Patents and
(c) all Know-How and other intellectual property of BioChemics directly related to the Products. 
 2.2 BioChemics Sale of Joint Patents to
Inpellis. BioChemics hereby sells, transfers, conveys, assign and delivers to Inpellis for the consideration specified below, an undivided joint ownership interest in (a) the Joint Patents, (b) all know-how and other intellectual
property of BioChemics directly related to the Joint Patents and (c) all know-how and other intellectual property of BioChemics related to the Products not conveyed pursuant to Section 2.1 above. 

2.3 No Implied Rights. No right under any other intellectual property of BioChemics is conveyed by implication under this Agreement. All such
rights are or shall be conveyed only as expressly provided in the terms of this Agreement. For the avoidance of doubt, it is understood and agreed that the transfers to Inpellis pursuant to this Agreement do not convey any right to practice the
BioChemics Intellectual Property in or for any purpose related to any products other than the Products. 
 2.4 Consideration. Inpellis has
paid BioChemics $750,000.00 on the Effective Date in full consideration for the conveyances provided for in this Agreement and BioChemics acknowledges receipt of such payment. 

2.5 Further Assurances. At any time and from time to time after the Effective Date, at the request of Inpellis and without further
consideration, BioChemics shall execute and deliver such other instruments of sale, transfer, conveyance and assignment and take such actions as Inpellis may reasonably request to more effectively transfer, convey and assign to Inpellis, and to
confirm Inpellis’s rights to, title in and ownership of, the property conveyed pursuant to this Agreement. 

  
 4 

	3.	Options to Purchase or License 

 3.1 Discoveries. In the event of the discovery or
development of a new drug compound, molecule or entity and/or new drug delivery or transport mechanisms (“Discovery”) by BioChemics, written notice of such Discovery will be provided to Inpellis with sufficient detail to enable evaluation
of the commercial application and potential of such Discovery. Such notice and its content shall constitute Confidential Information under Section 5.1 of this Agreement. Inpellis will, within the later of: (i) thirty (30) days of its
receipt of the aforementioned notice, or (ii) its receipt from BioChemics of further information requested as Inpellis deems required for its assessment of its commercial interest in licensing or purchasing such Discovery, provide to BioChemics
a notice of its intent to license or purchase such Discovery or to decline to proceed with any prospective license or purchase of same. If Inpellis elects to proceed then BioChemics and Inpellis will jointly secure an independent valuation expert to
appraise and value the Discovery in its then current state. Inpellis will then provide a reasonable development and commercialization plan to BioChemics for the transfer of the Discovery and related physical assets or manifestations to Inpellis by
license or sale, as the Parties may agree, and upon such terms as the Parties may agree. BioChemics may neither offer nor disclose the Discovery to other potential licensees or purchasers until the conclusion of the notice period(s) to Inpellis and
any subsequent negotiations have ended unsuccessfully. 
 3.2 Additional Products. In the event that Inpellis wishes to utilize the BioChemics
Intellectual Property or drug transport or delivery systems or mechanisms developed by BioChemics after the Effective Date in conjunction with drugs to relieve non-dermal pain, which drugs are not part of the Products, then Inpellis shall provide
written notice of its desire to use such drug(s) in and BioChemics shall, within thirty (30) days of receipt of such notice, propose to Inpellis in writing reasonable financial licensing terms and conditions for Inpellis’s use of such
drugs in conjunction with the BioChemics Intellectual Property for use within the Field. The Parties shall use all reasonable efforts to negotiate and agree upon such terms and conditions as soon as practicable after BioChemics makes it proposal. If
the Parties are not able to reach agreement within 30 days of the date on which BioChemics makes the initial proposal, then they shall retain a mutually agreeable independent expert to determine the terms and conditions. Each Party shall pay
one-half of the costs of retaining such expert  
 3.3 BioChemics Right to Repurchase. BioChemics shall, until December 31, 2017,
have the right to buy back from Inpellis the rights to the Caine Products (as defined in Schedule 1.15) conveyed pursuant to this Agreement for a payment of $750,000.00 in immediately available funds, provided that Inpellis shall retain joint
ownership of that property for the treatment of shingles. 
 3.4 BioChemics Right of First Offer. In the event Inpellis determines to sell any
of the property conveyed to it under this Agreement, it shall notify BioChemics of such determination. BioChemics shall notify Inpellis within 10 days of receiving such notice whether BioChemics 

  
 5 

 
wishes to negotiate to purchase such property. Upon receipt of such notice from BioChemics, Inpellis shall, prior to Inpellis selling such property to another party, negotiate in good faith with
BioChemics for a period not to exceed 30 days from the date of the notice from BioChemics to sell such property to BioChemics. 
  

	4.	Representations and Warranties 

 4.1 Mutual Representations, Warranties and Covenants. Each
Party represents, warrants and covenants as of the Effective Date to the other that: 
 (a) It is duly organized and validly existing
under the laws of its jurisdiction of incorporation or formation, and has all requisite corporate power and authority to carry out its business as presently conducted and as proposed to be conducted. 

(b) It is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing
this Agreement on its behalf has been duly authorized to do so by all requisite corporate action. 
 (c) This Agreement is legally binding
upon it, enforceable in accordance with its terms, except as limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of
creditors’ rights generally, or (ii) laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. The execution, delivery and performance of this Agreement by it does not conflict with, or
result in the breach of the terms of, any agreement, or instrument, to which it is a Party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction
over it. 
 (d) no consent, approval, authorization or order of any court or governmental agency or governmental body or Third Party is
required for execution and delivery by such Party of this Agreement. 
 4.2 BioChemics Representations and Warranties. BioChemics represents
and warrants to Inpellis that: 
 (a) the rights granted to Inpellis hereunder do not conflict with rights granted by BioChemics to any
Third Party. 
 (b) To BioChemics’s knowledge, the use of the property conveyed pursuant to this Agreement does not infringe any issued
patents of any Third Party. 
 (c) There are no agreements with, assignments by, restrictions, liens, or encumbrances on, disputes with, or
proceedings or claims against, BioChemics or its Affiliates relating to, affecting or limiting BioChemics’s rights with respect to the property conveyed under this Agreement. 

  
 6 

 (d) Schedules 1.9 and 1.14 together identify all of the pending patent applications and unexpired
patents that are Patents or Joint Patents owned by BioChemics as of the Effective Date. 
 (e) None of the patents or patent applications
owned by BioChemics and set forth on either Schedule 1.9 or Schedule 1.14 is, (i) subject to a pending interference action, opposition action, re-examination proceeding, litigation or other similar action by a Third Party challenging such
patents or patent applications, other than actions by Patent Authorities in connection with the prosecution of patent applications, or (ii) has been abandoned, or has been asserted to be invalid or unenforceable in a communication to BioChemics
or is subject to any inventorship proceeding or dispute. 
 4.3 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER
PARTY MAKES ANY REPRESENTATION AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL
CASES WITH RESPECT THERETO. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, BOTH PARTIES ACKNOWLEDGE AND DISCLAIM ANY WARRANTY AS TO THE USEFULNESS OR COMMERCIAL SUCCESS OF ANY PRODUCT OR THE ACHIEVEMENT OF DESIRED GOALS THROUGH USE OF BIOCHEMICS
INTELLECTUAL PROPERTY. 
 4.4 Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF SECTION 5 (CONFIDENTIALITY) AND WITHOUT PREJUDICE TO
THE OBLIGATION OF EITHER PARTY TO INDEMNIFY THE OTHER IN RESPECT OF CLAIMS BY A THIRD PARTY UNDER SECTION 6, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER INDIRECT DAMAGES
IN CONNECTION WITH THIS AGREEMENT; PROVIDED, HOWEVER THAT THIS SECTION 4.4 SHALL NOT BE CONSTRUED TO LIMIT DAMAGES AWARDED SPECIFICALLY IN RESPECT OF EITHER PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. 

 

	5.	Confidentiality 

 5.1 Confidentiality; Exceptions. Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree that each Party shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than for the purpose of exercising its retained rights
hereunder, or performing obligations hereunder, or as otherwise provided for in this Agreement, any confidential and proprietary information and materials of the other Party (collectively, “Confidential Information”). Notwithstanding the
foregoing, Confidential Information shall not include any information to the extent that it can be established by written documentation by the receiving party that such information: 

(a) was already known to the receiving party, at the time of disclosure, other than under an obligation of confidentiality (except to the
extent such obligation has expired or an exception is applicable under the relevant agreement pursuant to which such obligation established); 

  
 7 

 (b) was generally available to the public or otherwise part of the public domain at the time of
its disclosure to the receiving party; 
 (c) became generally available to the public or otherwise part of the public domain after its
disclosure and other than through any act or omission of the receiving party in breach of this Agreement; 
 (d) was independently
discovered or developed by the receiving party without reference to or use of Confidential Information of the disclosing party as demonstrated by documented evidence; or 

(e) was disclosed to the receiving party, other than under an obligation of confidentiality (except to the extent such obligation has
expired or an exception is applicable under the relevant agreement pursuant to which such obligation established), by a Third Party who had no obligation to the disclosing party not to disclose such information to others. 

The obligations set forth in this Section 5.1 shall remain in effect for five years. 

5.2 Authorized Disclosure. Except as expressly provided otherwise in this Agreement, each Party may use and disclose Confidential Information of
the other Party as follows: (i) under appropriate confidentiality provisions substantially equivalent to those in this Agreement (but for a confidentiality period that is reasonable and customary under the applicable circumstances) in
connection with the performance of its obligations or as reasonably necessary or useful in the exercise of its rights under this Agreement; (ii) to the extent such disclosure is reasonably necessary in prosecuting or maintaining any Patent or
other intellectual property right in accordance with this Agreement, prosecuting or defending litigation related to this Agreement, complying with applicable governmental regulations with respect to performance under this Agreement (including to
comply with the applicable rules of any public stock exchange upon which the stock of such Party or its Affiliate is listed), provided that the Party seeking to disclose Confidential Information of the other Party uses commercially reasonable
efforts, consistent with typical practice in the pharmaceutical industry, to secure confidential treatment thereof, as applicable; (iii) to the extent such disclosure is otherwise required by applicable law, provided, however, that if a
Party is required by applicable law or court order to make any such disclosure of the other Party’s Confidential Information it will, except where impracticable for necessary disclosures (for example, in the event of medical emergency), give
reasonable advance notice to the other Party of such disclosure requirement and, in each of the foregoing, (but not to the extent inappropriate in the case of prosecution and maintenance of Patents), will use its reasonable efforts to seek
confidential treatment of such Confidential Information required to be disclosed and limit disclosure of the Confidential Information to only that part necessary to comply with the request; any disclosure of Confidential Information as permitted in
the foregoing sentence shall not alter the confidential nature of such Confidential Information for all other purposes; (iv) in communication with advisors (including financial advisors, lawyers and accountants) or actual or bona fide potential
investors or acquirers, or actual or bona fide potential licensees or sublicensees related to Products, or approved or permitted contractors, service providers, vendors and the like used (or to be used) in connection with activities hereunder, each
on a need to know basis, and in each case under standard confidentiality obligations (subject to the allowances for term of 

  
 8 

 
confidentiality provided in subsection (i) above, except with respect to disclosures to actual or bona fide potential investors and acquirers receiving any technical data or information
related to the Licensed Products that is Confidential Information of the other Party shall be subject to obligations of confidentiality for a period of at least five (5) years after such disclosure, or (v) to the extent mutually agreed to
by the Parties. In addition to the foregoing, with respect to complying with the disclosure requirements of the U.S. Securities and Exchange Commission (“SEC”) or similar regulatory bodies or the rules of an applicable public stock
exchange, in connection with any required disclosure of material information related to this Agreement, the Parties shall consult with one another concerning the information to be disclosed and secure confidential treatment thereof where
practicable. If time does not permit such discussion, or if after such discussion between counsel, the Party desiring to make the disclosure still believes such Party is required by applicable Law or applicable stock exchange rule to make such
disclosure, it may do so, upon written notice to the other Party. For clarity, nothing in this Section 5.2 shall prevent any Party from making disclosures required by applicable law. 

 

	6.	Indemnification 

 6.1 Indemnification by Inpellis. Inpellis agrees to indemnify, defend and
hold harmless BioChemics and its Affiliates and their officers, directors, shareholders, employees and agents (“BioChemics Indemnitees”) from and against any and all claims, costs, expenses, damages and liabilities, including reasonable
attorney’s fees (“Losses”) to which the BioChemics Indemnitees may become subject as a result of any claim, demand, action or other proceeding by any Third Party (a) arising out of the research, use, testing, exploitation,
development, commercialization, import, export, sale, offer for sale, and any transfer of any Products developed or commercialized by Inpellis, its Affiliates and/or licensees, or (b) from the breach of any of Inpellis’s obligations
hereunder or (c) alleging infringement of Third Party intellectual property rights by use of Inpellis intellectual property in the research, development, manufacture, Commercialization, use, import, export, sale, offer for sale and/or any
transfer of any of the Products, except to the extent such Losses result from (i) the negligence or willful misconduct of BioChemics or any of the BioChemics Indemnitees; (ii) breach of this Agreement by BioChemics or any of the BioChemics
Indemnitees; (iii) any claim by a Third Party alleging that the grant of rights by BioChemics to Inpellis under this Agreement violates or conflicts with the terms of any license or other grant of rights by BioChemics to such Third Party; or
(iv) any claims by a Third Party alleging infringement of Third Party intellectual property rights in the development of the Products or commercialization, use, import, export, sale, offer for sale and/or any transfer of the Products. 

6.2 Indemnification by BioChemics. BioChemics shall indemnify, defend and hold harmless Inpellis and its Affiliates and their officers,
directors, shareholders, employees and agents (“Inpellis Indemitees”) from and against any and all Losses to which the Inpellis Indemnitees may become subject as a result of any claim, demand, action or other proceeding by any Third Party
(i) alleging infringement of Third Party intellectual property rights in the research, development, commercialization, use, import, export, sale, offer for sale and/or any transfer of the Products or (ii) breach of this Agreement by
BioChemics, except to the extent such Losses result from (i) the negligence or willful misconduct of Inpellis or any of the Inpellis Indemnitees or, (ii) breach of this Agreement by Inpellis or any of the Inpellis Indemnitees. 

  
 9 

 6.3 Apportionment of Fault. If any Losses occur by reason of or result from the joint fault of
Inpellis and BioChemics, liability for such Losses under 6.1 and 6.2 shall be apportioned between Inpellis and BioChemics according to the relative fault of Inpellis and BioChemics. 

6.4 Claim for Indemnification. Whenever any Claim shall arise for indemnification under this Section 6, the Inpellis Indemnitees and the
BioChemics Indemnitees entitled to indemnification (the “Indemnified Party”) shall promptly notify the other Party (the “Indemnifying Party”) in writing of the Claim and, when known, the facts constituting the basis for the
Claim. The Indemnified Party’s failure to notify the Indemnifying Party will not relieve the Indemnifying Party from any liability to such Indemnified Party under this Section 6 except to the extent any liability results from the failure
to timely notify the Indemnifying Party. The Indemnifying Party shall promptly assume, and have the right to control, the defense and settlement thereof at its own expense. The Indemnified Party shall not settle or compromise any Claim by a Third
Party for which it is entitled to indemnification under this Section 6 without the prior written consent of the Indemnifying Party, unless the Indemnifying Party is in breach of its obligation to defend hereunder. In no event shall either the
Indemnified Party or Indemnifying Party settle any Claim without the prior written consent of the Indemnified Party if such settlement does not include a release from liability on such Claim or if such settlement would involve undertaking an
obligation other than the payment of money by the settling party that would bind or impair the non-settling party, or result in any patent or trademark of the other party being rendered invalid or unenforceable, or if such settlement contains an
admission that any patent is invalid or unenforceable. 
  

	7.	Miscellaneous Provisions 

 7.1 Dispute Resolution. If any dispute arises between the
Parties out of or in connection with this Agreement, the Parties shall first attempt to resolve such dispute in accordance with the dispute resolution procedures set forth on Exhibit 7.1 hereto. 

7.2 Governing Law; Waiver of Jury Trial. This Agreement shall be governed in all respects by the laws of the Commonwealth of Massachusetts, USA,
without regard to its choice of law provisions. BIOCHEMICS AND INPELLIS EACH KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHT EACH MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION AMONG THEM AND/OR THEIR AFFILIATES BASED HEREON OR
ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE OTHER PARTIES IN CONNECTION HEREWITH. 

7.3 Consent to Jurisdiction. BioChemics and Inpellis each irrevocably consent that any action or proceeding among the Parties and/or their
Affiliates, under, arising out of or in any manner relating to this Agreement shall be brought in the United States District Court for the District of Massachusetts. BioChemics and Inpellis hereby each expressly and irrevocably assent and submit to
the personal jurisdiction of any such court in any such action or proceeding. BioChemics and Inpellis each further irrevocably consent to the service of summons, notice, or other process relating to any such action or proceeding by delivery thereof
by hand or by mail in the manner 

  
 10 

 
provided for in Section 7.11 of this Agreement and consent that it may be served with any process or paper by registered mail or by personal service within or without the Commonwealth of
Massachusetts, as the case may be, in accordance with applicable law. BioChemics and Inpellis each waive any objection, claim or defense which it may have at any time to the laying of venue of any such action or proceeding in any such court;
irrevocably waive any claim that any such action or proceeding brought in any such court has been brought in an inconvenient forum; and further irrevocably waive the right to object, with respect to any such action or proceeding brought in any such
court, that such court does not have jurisdiction over such Party. 
 7.4 Equitable Relief. Notwithstanding Paragraph B (7) of Exhibit
7.1, each Party hereto acknowledges that the remedies at law of the other Party for a breach or threatened breach of this Agreement would be inadequate and, in recognition of this fact, any Party to this Agreement, without posting any bond, and in
addition to all other remedies that may be available, shall be entitled to seek equitable relief in the form of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy in a court of
competent jurisdiction that may then be available. 
 7.5 Entire Agreement; Modification. This Agreement (including the Exhibits hereto)
represents the final expression of the Parties’ agreement and a complete and exclusive statement with respect to all of its respective terms. This Agreement supersedes all prior and contemporaneous agreements and communications. No trade
customs, courses of dealing or courses of performance by the Parties shall be relevant to modify, supplement or explain any term(s) used in this Agreement. This Agreement may only be modified or supplemented in a writing and signed by the Parties to
this Agreement. 
 7.6 Relationship Between the Parties. The Parties’ relationship, as established by this Agreement, is solely that of
independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal representative of the other Party; neither Party can assume or create any
obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. 
 7.7
Non-Waiver. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that
provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time
and shall be signed by such Party. 
 7.8 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or
obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that (a) either Party may assign this
Agreement, and its rights and obligations hereunder, to an Affiliate, provided that such Party shall remain liable and responsible to the other Party for the performance and observance of all such duties and obligations by such Affiliate; and
(b) either Party may assign this Agreement, and its rights and obligations hereunder, to a Third Party in 

  
 11 

 
connection with the transfer or sale of all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise,
provided that the assigning party shall remain liable and responsible to the non-assigning party for the performance and observance of all such duties and obligations by such Third Party. The rights and obligations of the Parties under this
Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be void. 

7.9 No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the benefit of any Party other than those executing
it. 
 7.10 Severability. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of
competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the
original Agreement had been executed without the invalidated. unenforceable or illegal part. 
 7.11 Notices. Any notice to be given under
this Agreement must be in writing and delivered either (a) in person, (b) by any method of mail (postage prepaid) requiring return receipt, (c) by overnight courier confirmed thereafter to the Party to be notified at its address(es)
given below, or at any address such Party has previously designated by prior written notice to the other, or (d) by sending it by facsimile to the facsimile number of the other Party as stated below. Notice shall be deemed sufficiently given
for all purposes upon the earlier of (x) the date of actual receipt; (y) if mailed, five business days after the date of postmark; or (z) if delivered by overnight courier, the next business day the overnight courier regularly makes
deliveries. 
 if to Inpellis. notices must be addressed to: 

Inpellis, Inc. 
 30 Washington
Avenue 
 Suite F 
 Haddonfield,
NJ 08033 
 Attn: Chief Executive Officer 

Facsimile: (978) 750-0085 
 If to
BioChemics, notices must be addressed to: 
 BioChemics, Inc. 

300 Rosewood Drive 
 Suite 103

 Danvers, MA. 01923 
 Attn:
Chief Executive Officer 
 Facsimile: (978) 750-0085 

  
 12 

 7.12 Force Majeure. Except for the obligation to make payment when due, each Party shall be excused
from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party’s reasonable control including but not limited to acts of God, fire, flood, explosion, earthquake, or other
natural forces, war, civil unrest, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labor disturbance, or any other event similar to those
enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Notice of a Party’s
failure or delay in performance due to force majeure must be given to the other Party within ten days after its occurrence. All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such
force majeure. 
 7.13 No Use of Names. Except as otherwise provided herein, nothing contained in this Agreement shall be construed as
conferring any right on either Party to use in advertising, publicity or other promotional activities any name, trade name, trademark or other designation of the other Party, including any contraction, abbreviation or simulation of any of the
foregoing, unless the express written permission of such other Party has been obtained. 
 7.16 Counterparts. This Agreement may be executed
in two counterparts, each of which shall be deemed an original document, and both of which, together with this writing, shall be deemed one instrument. 

[SIGNATURE PAGE FOLLOWS] 

  
 13 

 IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement. 

 

			
	BioChemics, Inc.
		
	By:	 	 /s/ Marshall S. Sterman

	Name:	 	Marshall S. Sterman
	Title:	 	Chief Executive Officer
	Date:	 	October 24, 2015
	
	Inpellis, Inc.
		
	By:	 	 /s/ Patrick T. Mooney, M.D.

	Name:	 	Patrick T. Mooney, M.D.
	Title:	 	Chief Executive Officer
	Date:	 	October 24, 2015

  
 14 

 SCHEDULE 1.15 

Products 
 Transdermal Ibuprofen

 Transdermal Benfothiamine 
 Transdermal Gabapentin 

Transdermal Celecoxib 
 Transdermal Rofecoxib 

Transdermal Lidocaine and any similar products derived from the same chemical including, without limitation, Benzocaine, Dibucaine, Oxybuprocaine,
Proparacaine, Proxymetacaine, Tetracaine, Amethocaine, Xylocaine and Lignocaine (collectively, the “Caine Products”) 

  
 15 

 SCHEDULE 1.14 

Patents 
  

					
	 Attorney Ref. No.
	  	 Title
	  	 Application Information

	 3326/109AU
 (Australian Patent

Application)
	  	IBUPROFEN FOR TOPICAL ADMINISTRATION	  	 Appl No.: 2009291755
 Filed September 10,
2009
 (Priority 61/095,672, Filed September 10, 2008)

			
	3326/109CA (Canadian Patent Application)	  	IBUPROFEN FOR TOPICAL ADMINISTRATION	  	 Appl No.: 2,749,941
 Filed: September 10,
2009
 (Priority 61/095,672, Filed September 10, 2008)

			
	3326/109EP (European Patent Application)	  	IBUPROFEN FOR TOPICAL ADMINISTRATION	  	 Appl No.: 09792433.6
 Filed: September 10,
2009
 Publication No. EP 2373346,
 Published
October 12, 2011

			
	3326/109WO (PCT Patent Application)	  	IBUPROFEN FOR TOPICAL ADMINISTRATION	  	 Appl No.: PCT/US2009/056568
 Filed September 10,
2009
 (Priority: 61/095,672, Filed September 10, 2008)

Publication No. WO
 2010/030821, Published
March 18, 2010

			
	 3326/112
 (U.S. Utility Application)
	  	IBUPROFEN FOR TOPICAL ADMINISTRATION	  	 Appl No.: 13/604,040
 Filed September 5,
2012
 (Priority: 61/095,672 Filed September 10, 2008)
 CON
of 12,557,490 filed Sept. 10, 2009 (3326/109)
 Publication No. US 2012-0329875 A1,

Published December 27, 2012

			
	3326/117	  	TOPICAL AND TRANSDERMAL IBUPROFEN-CONTAINING COMPOSITION	  	 Appl No.:
 Filed:

  
 16 

 Schedule 1.9 

Joint Patents 
  

					
	 ATTORNEY

REF. NO.
	  	 TITLE
	  	 APPLICATION

INFORMATION

	 3326/110
  

(US Utility Application)
	  	TRANSDERMAL DRUG DELIVERY USING AN OSMOLYTE AND VASOACTIVE AGENT	  	 App. No. 12/584,841
 Filed: September 22,
2009
 (Priority: 61/099, 129, Filed September 22, 2008)

			
		  		  	Publication No. US 2010/0076035 A1,
		  		  	Published March 25, 2010
			
	 3326/110EP
  

(European Patent Application)
	  	TRANSDERMAL DRUG DELIVERY USING AN OSMOLYTE AND VASOACTIVE AGENT	  	 Appl. No.: 09740777.9
 Filed: September 22,
2009
 (Priority. 61/099,129, Filed September 22, 2008)

			
		  		  	Publication No. EP 2207536,
		  		  	Published July 21, 2010
			
	 3326/110MX
  

(Mexican Patent Application)
	  	TRANSDERMAL DRUG DELIVERY USING AN OSMOLYTE AND VASOACTIVE AGENT	  	 Appl. No.: MX/A/2010/004169
 Filed: September
22, 2009
 (Priority: 61/099,129, Filed September 22, 2008)

			
	 3326/110WO
  

(PCT Patent Application)
	  	TRANSDERMAL DRUG DELIVERY USING AN OSMOLYTE AND VASOACTIVE AGENT	  	 Appl. No.: PCT/US2009/057916
 Filed: September
22, 2009
 (Priority: 61/099,129, Filed September 22, 2008)

			
		  		  	Publication No. WO 2010/034019,
		  		  	Published March 25, 2010
			
	 3326/116WO

(PCT Application)
	  	TOPICAL FORMULATIONS AND METHODS FOR DRUG DELIVERY	  	 Appl. No.: PCT/US14/29240
 Files:
14-Mar-2014

			
		  		  	(Priority: 61/790,126 filed March 15, 2013)
		  		  	Publication No. WO 2014/144752,
		  		  	Published September 18, 2014

  
 17 

					
	 ATTORNEY

REF. NO.
	  	 TITLE
	  	 APPLICATION

INFORMATION

	484P005-CA (Canadian Patent Application)	  	SOLUTION-BASED TRANSDERMAL DRUG DELIVERY SYSTEM	  	 Appl. No. 2,360,590
 Filed: October 23,
2001

			
	 484P005-US
  

(US Patent Application)
	  	SOLUTION-BASED TRANSDERMAL DRUG DELIVERY SYSTEM	  	 Appl. No. 09/698,483
 Filed: October 27,
2000

			
	 484P005-Australia

 
 (Australian Patent Application)
	  	SOLUTION-BASED TRANSDERMAL DRUG DELIVERY SYSTEM	  	 Appl. No.: 2001179417
 Filed: October 15,
2001

			
	 484009-Australia
  

(Australian Patent Application)
	  	METHODS OF DEVICE-ASSISTED DRUG DELIVERY	  	 Appl. No.: 2005286822
 Filed: September 20,
2005

			
	 484P009-Canada

(Canadian Patent Application)
	  	METHODS OF DEVICE-ASSISTED DRUG DELIVERY	  	 Appl. No.: 2,569,285
 Filed: September 20,
2005

			
	 484P009-Brazil

(Brazilian Patent Application)
	  	METHODS OF DEVICE-ASSISTED DRUG DELIVERY	  	 Appl. No.: P10513446-3
 Filed: September 20,
2005

			
	 484P009-India

(Indian Patent Application)
	  	METHODS OF DEVICE-ASSISTED DRUG DELIVERY	  	 Appl. No.: 7601/DelNp/2006
 Filed: December 16,
2006

			
	 484P009-Mexico lx/a
  

(Mexican Patent Application)
	  	METHODS OF DEVICE-ASSISTED DRUG DELIVERY	  	 Appl. No.: 2007/001222
 Filed: January 30,
2007

			
	 484P011-US

(US Patent Application)
	  	BIFUNCTIONAL SYNTHETIC MOLECULES	  	 Appl. No. 11/820,172
 Filed: June 18,
2007

			
	484P011-US (Canadian Patent Application)	  	BIFUNCTIONAL SYNTHETIC MOLECULES	  	 Appl. No.: 2,690,357
 Filed: June 17,
2008

  
 18 

					
	 ATTORNEY

REF. NO.
	  	 TITLE
	  	 APPLICATION

INFORMATION

	484P011-Europe (European Patent Application)	  	BIFUNCTIONAL SYNTHETIC MOLECULES	  	 Appl. No.: 8768535.9
 Filed: June 17, 2008

 
 2167104-Pub

March 31, 2010

			
	 484P011-Hong Kong
  

(Hong Kong Patent Application)
	  	BIFUNCTIONAL SYNTHETIC MOLECULES	  	 Appl. No.: HK1142815
 Filed: December 17,
2010

			
	 484P011-India

(India Patent Application)
	  	BIFUNCTIONAL SYNTHETIC MOLECULES	  	 Appl. No.: 551/DELNP/2009
 Filed: December 29,
2009

			
	 484P011-Mexico

(Mexican Patent Application)
	  	BIFUNCTIONAL SYNTHETIC MOLECULES	  	 Appl. No.: lx/a2009013759
 Filed: December 15,
2009

  
 19 

 EXHIBIT 7.1 

Alternative Dispute Resolution Procedures 

A. METHOD OF INVOKING ADR PROCEDURES 
 1. These procedures may be
invoked by any Party by giving written notice to the other of the dispute and designating one or more persons (collectively, the “DESIGNEE”) to act on behalf of the disputing Party regarding the dispute. The other Party shall be required
to respond to the disputing Party’s notice within ten (10) business days by designating in writing its own Designee. A Party may choose to represent itself, or if it appoints a Designee, its officers may nonetheless attend such meetings.

 2. The Parties, each acting through its Designee, shall meet at a mutually acceptable time and place within ten (10) business days after the
non-disputing Party designates its Designee to the others. At that meeting, the Parties shall attempt in good faith to negotiate a resolution of the dispute, or failing that, to agree on a method for resolving the claim or dispute. 

3. If, within ten (10) business days after the first meeting or within such longer period of time as the Parties may mutually agree, the Parties have not
succeeded in negotiating a resolution of the claim or dispute or agreeing on a dispute resolution mechanism, they shall submit the dispute to mediation in accordance with the procedures set forth herein. 

4. The Parties will jointly appoint a mutually acceptable mediator to mediate the dispute. If the Parties are unable to agree on a mutually acceptable
mediator within five (5) business days after the conclusion of the negotiations described in Paragraph 3 above, then the Parties shall select a neutral Person from American Arbitration Association (“AAA”) in New York, New York, with
the assistance of AAA, unless the Parties agree otherwise in finding a mutually acceptable mediator. 
 5. The non-prevailing Party in the dispute shall be
responsible for the payment of the fees and costs of the mediator, and any fees and costs of AAA. 
 6. The Parties agree to participate in good faith in
the mediation and negotiations related thereto for a period of thirty (30) days from appointment of a mediator by any of the Parties or the AAA. 
 7.
The Parties agree that the mediation period may be extended for an additional thirty (30) days beyond the initial thirty (30) day period upon agreement of the Parties. Either Party may terminate the mediation at any time after the initial
thirty (30) days or when any agreed upon extension has expired. 

  
 20 

 B. MEDIATION PROCEDURES 

1. The mediator shall be neutral and impartial. 
 2. The mediator
shall control the procedural aspects of the mediation. The Parties will cooperate fully with the mediator. 
 a. The mediator is free to meet and
communicate separately with each Party. 
 b. The mediator will decide when to hold joint meetings with the Parties and when to hold separate meetings.
There shall be no stenographic record of any meeting. Formal rules of evidence will not apply. 
 3. Each Party may be represented by more than one person,
including an attorney. 
 4. The process will be conducted expeditiously. 

5. The mediator will not transmit information received from any Party to another Party or any third person unless authorized to do so by the Party
transmitting the information. 
 6. The entire process is confidential. The Parties and the mediator will not disclose information regarding the process,
including settlement terms, to third persons, unless the Parties otherwise agree. The process shall be treated as a compromise negotiation for purposes of the applicable rules of evidence. Further, the Parties will not disclose the existence of a
dispute or information regarding the mediation to third persons including, without limitation, the media. 
 7. The Parties will refrain from pursuing
administrative and/or judicial remedies during the mediation process, except as otherwise expressly provided in the agreement which incorporates these procedures. The Parties agree that any and all statutes of limitation or periods of time for
taking action shall be tolled during the time period that the Parties are engaged in mediation. 
 8. Unless all Parties and the mediator otherwise agree in
writing: 
 a. The mediator will be disqualified as a witness, consultant or expert in any pending or future investigation, action or proceeding relating to
the subject matter of the mediation (including any investigation, action or proceeding which involves persons not Parties to this mediation); 
 b. The
mediator, at the conclusion of the mediation, will immediately either destroy and certify destruction of, or return to the providing Party, any and all documents and information in the mediator’s possession, whether or not the mediation was
successful; and 
 c. The mediator will not be subpoenaed in any such investigation, action or preceding and all Parties will oppose any effort to have the
mediator subpoenaed. 
 9. The mediator, if a lawyer, may freely express views to the Parties on the legal issues of the dispute. 

  
 21 

 10. The mediator shall not be liable for any act or omission in connection with the mediation. 

11. The mediator may withdraw at any time by written notice to the Parties (i) for overriding personal reasons, (ii) if the mediator believes that a
Party is not acting in good faith, or (iii) if the mediator concludes that further mediation efforts would not be useful. 

  
 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]